Focus & Strategy
Executive Chairman & Chief Executive Officer’s Letter
Leadership
Board of Directors
Innovation & Pipeline
Roluperidone (MIN-101)
Seltorexant (MIN-202)
MIN-117
MIN-301
Disease Areas
Schizophrenia
Major Depressive Disorder
Insomnia and Mood Disorders
Parkinson’s Disease
Investors & Media
Investors & Media Portal
Press Releases
Events & Presentations
Corporate Governance
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials & Filings
SEC Filings
Annual Reports and Proxies
Quarterly Results
Key Ratios
Stock Information
Historic Stock Lookup
Investment Calculator
Analyst Coverage
Investor FAQs
Contact
Focus & Strategy
Executive Chairman & Chief Executive Officer’s Letter
Leadership
Board of Directors
Innovation & Pipeline
Roluperidone (MIN-101)
Seltorexant (MIN-202)
MIN-117
MIN-301
Disease Areas
Schizophrenia
Major Depressive Disorder
Insomnia and Mood Disorders
Parkinson’s Disease
Investors & Media
Investors & Media Portal
Press Releases
Events & Presentations
Corporate Governance
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials & Filings
SEC Filings
Annual Reports and Proxies
Quarterly Results
Key Ratios
Stock Information
Historic Stock Lookup
Investment Calculator
Analyst Coverage
Investor FAQs
Contact
Nasdaq NERV
Schizophrenia
READ MORE
Major Depressive Disorder (MDD)
READ MORE
Insomnia
READ MORE
Parkinson's Disease
READ MORE
Schizophrenia
READ MORE
Major Depressive Disorder (MDD)
READ MORE
Insomnia
READ MORE
Parkinson's Disease
READ MORE
FOCUS & STRATEGY
Read More
Innovation & Pipeline
Read More
Investors & Media
Read More
Your browser is out-of-date!
Update your browser to view this website correctly.
Update my browser now
×
